Omniscient Neurotechnology

Omniscient Neurotechnology develops AI-powered connectomic analysis software for precision brain mapping and surgical planning. The company specializes in digital brain mapping technology that generates personalized connectomes—computational maps of brain functional and structural connections—using advanced algorithms and cloud-based processing of MRI and resting-state functional MRI (rs-fMRI) data. Quicktome is their flagship platform, an automated connectomic analysis solution designed for neurosurgeons and researchers to extract actionable insights into patient-specific brain networks prior to surgery and for large-scale neural data processing in research settings. The platform supports clinical decision-making across neurologic conditions including cranial surgery, neuro-oncology, depression, Alzheimer's disease, schizophrenia, and stroke. By automating what historically required manual tractography and reducing processing time from hours to under 2 hours with minimal clinician intervention, Quicktome enables faster surgical planning while preserving critical functional brain regions. The company operates through global distribution partnerships and maintains offices in Australia (Sydney, NSW) and the United States (Atlanta). Omniscient holds SOC 2 compliance certification and patents issued by the USPTO. The technology is positioned at the intersection of neuroimaging, artificial intelligence, and cloud computing, serving both clinical and research institutions worldwide.